Anti-Human CD19 (Loncastuximab) (C3160-50mg)

CD19 is a 95 kDa type I transmembrane glycoprotein found on the surface of B cells at all stages of their growth into plasma cells. It works as a co-receptor alongside the B cell receptor (BCR) and is essential in activating, growing, and transforming B cells. CD19 assists in lowering the threshold for BCR signaling, making B cells more sensitive to antigens. Because of its crucial involvement in the life of B cells, CD19 is an important marker for identifying B cell lineage and is a target for treatments focusing on B cell-related cancers1-7. ADCT-402, also known as loncastuximab tesirine, is an antibody-drug conjugate (ADC) that targets CD19-expressing cells. It is made up of a humanized monoclonal antibody that targets CD19 and is linked to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. When ADCT-402 binds to CD19- expressing cells, it is taken inside the cell, and the cytotoxin is released, leading to DNA crosslinking and cell death. This targeted approach allows for strong and selective anti-tumor activity against CD19-expressing blood cancers, such as B-cell lymphomas and leukemias8,9. This non-therapeutic biosimilar is not a drug conjugate and thus does not contain the cytotoxin PDB.